245 related articles for article (PubMed ID: 12230093)
21. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
[TBL] [Abstract][Full Text] [Related]
22. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment].
Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L
Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735
[TBL] [Abstract][Full Text] [Related]
23. Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging.
Giraudo C; Karanikas G; Weber M; Raderer M; Jaeger U; Simonitsch-Klupp I; Mayerhoefer ME
J Magn Reson Imaging; 2018 May; 47(5):1217-1226. PubMed ID: 29086453
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
[TBL] [Abstract][Full Text] [Related]
25. [SPECT-CT 67Ga studies in lymphoma disease. Contribution to staging and follow-up].
Fuertes Manuel J; Estorch Cabrera M; Camacho Martí V; Flotats Giralt A; Rodríguez-Revuelto AA; Hernández Fructuoso MA; Carrió Gasset I
Rev Esp Med Nucl; 2006; 25(4):242-9. PubMed ID: 16827987
[TBL] [Abstract][Full Text] [Related]
26. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
27. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma.
Tatsumi M; Kitayama H; Sugahara H; Tokita N; Nakamura H; Kanakura Y; Nishimura T
J Nucl Med; 2001 Apr; 42(4):601-8. PubMed ID: 11337549
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET/CT in re-staging of patients with lymphoma.
Freudenberg LS; Antoch G; Schütt P; Beyer T; Jentzen W; Müller SP; Görges R; Nowrousian MR; Bockisch A; Debatin JF
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):325-9. PubMed ID: 14647988
[TBL] [Abstract][Full Text] [Related]
29. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy.
Delcambre C; Reman O; Henry-Amar M; Peny AM; Macro M; Cheze S; Génot JY; Tanguy A; Switsers O; Van HL; Couëtte JE; Leporrier M; Bardet S
Eur J Nucl Med; 2000 Feb; 27(2):176-84. PubMed ID: 10755723
[TBL] [Abstract][Full Text] [Related]
30. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
[TBL] [Abstract][Full Text] [Related]
31. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.
Moog F; Kotzerke J; Reske SN
J Nucl Med; 1999 Sep; 40(9):1407-13. PubMed ID: 10492357
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil.
Cerci JJ; Pracchia LF; Soares Junior J; Linardi Cda C; Meneghetti JC; Buccheri V
Clinics (Sao Paulo); 2009; 64(6):491-8. PubMed ID: 19578651
[TBL] [Abstract][Full Text] [Related]
33. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
[TBL] [Abstract][Full Text] [Related]
34. Progress in medical imaging of lymphoma and Hodgkin's disease.
Bangerter M; Griesshammer M; Bergmann L
Curr Opin Oncol; 1999 Sep; 11(5):339-42. PubMed ID: 10505769
[TBL] [Abstract][Full Text] [Related]
35. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan.
Hong SP; Hahn JS; Lee JD; Bae SW; Youn MJ
Yonsei Med J; 2003 Oct; 44(5):779-86. PubMed ID: 14584092
[TBL] [Abstract][Full Text] [Related]
36. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.
Moon SH; Cho SK; Kim WS; Kim SJ; Chan Ahn Y; Choe YS; Lee KH; Kim BT; Choi JY
J Nucl Med; 2013 Jul; 54(7):1039-44. PubMed ID: 23658217
[TBL] [Abstract][Full Text] [Related]
37. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
38. Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study.
Bar-Shalom R; Yefremov N; Haim N; Dann EJ; Epelbaum R; Keidar Z; Gaitini D; Frenkel A; Israel O
Radiology; 2003 May; 227(2):353-60. PubMed ID: 12637679
[TBL] [Abstract][Full Text] [Related]
39. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
[TBL] [Abstract][Full Text] [Related]
40. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
